HE4和CA125对上皮性卵巢癌治疗效果评价.docVIP

HE4和CA125对上皮性卵巢癌治疗效果评价 　　【摘要】 目的：探讨人附睾蛋白（HE4）和糖蛋白125（CA125）在上皮性卵巢癌（epithelial ovarian cancer，EOC）临床疗效评价中的应用价值。方法：选取2014年7月-2016年12月本院收治的EOC患者44例，手术联合术后化疗37例，新辅助化疗患者7例。观察比较术前（初诊）、术后、化疗前、化疗第2次的血清CA125、HE4表达水平，以及分析化疗第2次的血清HE4、CA125的表达水平变化与肿瘤分期、组织病理类型、是否接受卵巢癌减灭术之间的相关性。结果：患者术后的血清CA125、HE4分别为（54.45±15.02）U/mL、（79.14±22.71）pmol/L，低于术前的（207.39±41.13）U/mL、 　　（226.05±36.08）pmol/L（P0.05）；化疗第2次的血清CA125、HE4分别为（23.60±4.52）U/mL、（32.36±10.33）pmol/L，低于化疗前的（58.39±8.74）U/mL、（81.52±10.04）pmol/L（P0.05）。多元线性回归分析显示，肿瘤分期为Ⅲ期、卵巢浆液性腺癌及子宫内膜样腺癌、未接受卵巢癌减灭术是导致血清HE4升高的危险因素（P0.05）；肿瘤分期为Ⅲ期、未接受卵巢癌减灭术是导致血清CA125升高的危险因素（P0.05）。结论：HE4和CA125用于评价EOC具有高度可行性。 　　【关键词】 上皮性卵巢癌； HE4； CA125； 疗效； 评价 　　【Abstract】 Objective：To investigate the clinical value of human epididymis protein（HE4） and glycoprotein 125（CA125） in evaluation of clinical efficacy of epithelial ovarian cancer（EOC）.Method：44 patients with EOC admitted to our hospital from July 2014 to December 2016 were selected，surgery combined with postoperative chemotherapy in 37 cases，neoadjuvant chemotherapy in 7 cases.Before operation，after operation，before chemotherapy，after chemotherapy，the levels of serum CA125 and HE4 were observed and compared before，and the correlation between the changes of serum HE4 and CA125 expression and tumor staging，histopathological types，and whether or not ovarian cancer surgery was reduced was analyzed.Result：After operation，the serum CA125 and HE4 were（54.45±15.02）U/mL and（79.14±22.71）pmol/L respectively，which were lower than （207.39±41.13）U/mL and（226.05±36.08）pmol/L before operation（P0.05）.After chemotherapy，the serum CA125 and HE4 were（23.60±4.52）U/mL and（32.36±10.33）pmol/L respectively，which were lower than （58.39±8.74）U/mL and（81.52±10.04）pmol/L before chemotherapy（P0.05）.Multiple linear regression analysis showed that the stage of tumor was stage Ⅲ，ovarian serous adenocarcinoma and endometrioid adenocarcinoma，not receiving ovarian cancer cytoreductive surgery were the risk factors leading to elevated serum HE4（P0.